Welcome to RealPatient
RealPatient is your self-guided tour through published sources of CAR-T real world evidence
Select patient profiles of interest and view relevant real-world outcomes in specific populations quickly and simply. Latest data sources are updated regularly.
Who is your CAR-T patient?
Tisagenlecleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.